{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:50:34Z","timestamp":1791561034954,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clinre.2025.102741","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:38:48Z","timestamp":1764981528000},"page":"102741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Five-year effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6676-1222","authenticated-orcid":false,"given":"Aur\u00e9lien","family":"Amiot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Kirchgesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadrien","family":"Alric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Tr\u00e9ton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Uzzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Hammoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Allez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Bresteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoram","family":"Bouhnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Seksik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Carbonnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10080","key":"10.1016\/j.clinre.2025.102741_bib0001","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Peyrin-Biroulet L. Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clinre.2025.102741_bib0002","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102741_bib0003","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/apt.13835","article-title":"Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014","volume":"45","author":"Kirchgesner","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.clinre.2025.102741_bib0004","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102741_bib0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.dld.2020.10.018","article-title":"Clinical guidelines for the management of inflammatory bowel disease: update of a French national consensus","volume":"53","author":"Amiot","year":"2021","journal-title":"Dig Liver Dis"},{"issue":"10","key":"10.1016\/j.clinre.2025.102741_bib0006","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: medical Treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"20","key":"10.1016\/j.clinre.2025.102741_bib0007","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clinre.2025.102741_bib0008","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clinre.2025.102741_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2025.102591","article-title":"Efficacy and safety of intravenous vedolizumab treatment in Chinese patients with moderate-to-severe Crohn\u2019s disease","volume":"49","author":"Chen","year":"2025","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102741_bib0010","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/apt.16714","article-title":"Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn\u2019s disease refractory to anti-tumour necrosis factor","volume":"55","author":"Parrot","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.clinre.2025.102741_bib0011","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/apt.15706","article-title":"The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn\u2019s disease refractory to anti-tumour necrosis factor","volume":"51","author":"Alric","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.clinre.2025.102741_bib0012","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.clinre.2025.102741_bib0013","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/apt.15609","article-title":"A clinical decision support tool may help to optimise vedolizumab therapy in Crohn\u2019s disease","volume":"51","author":"Dulai","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.clinre.2025.102741_bib0014","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1016\/j.cgh.2020.02.010","article-title":"Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis","volume":"18","author":"Dulai","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102741_bib0015","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/ibd\/izac105","article-title":"Feasibility of a Clinical Decision Support Tool for Ustekinumab to Predict Clinical Remission and Relapse in Patients With Crohn\u2019s Disease: a Multicenter Observational Study","volume":"29","author":"Park","year":"2023","journal-title":"Inflamm Bowel Dis"},{"issue":"398","key":"10.1016\/j.clinre.2025.102741_bib0016","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/01621459.1987.10478441","article-title":"Model-Based Direct Adjustment","volume":"82","author":"Rosenbaum","year":"1987","journal-title":"J Am Stat Assoc"},{"issue":"28","key":"10.1016\/j.clinre.2025.102741_bib0017","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"30","key":"10.1016\/j.clinre.2025.102741_bib0018","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1002\/sim.7084","article-title":"Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis","volume":"35","author":"Austin","year":"2016","journal-title":"Stat Med"},{"key":"10.1016\/j.clinre.2025.102741_bib0019","series-title":"R core team R: a language and environment for statistical computing","year":"2020"},{"issue":"9","key":"10.1016\/j.clinre.2025.102741_bib0020","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1097\/MEG.0000000000002817","article-title":"Vedolizumab versus ustekinumab in Crohn\u2019s disease with prior anti-tumor necrosis factor failure: an updated meta-analysis","volume":"36","author":"Milioli","year":"2024","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.clinre.2025.102741_bib0021","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn\u2019s disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"13","key":"10.1016\/j.clinre.2025.102741_bib0022","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.cgh.2019.04.040","article-title":"Should We Divide Crohn\u2019s Disease Into Ileum-Dominant and Isolated Colonic Diseases?","volume":"17","author":"Dulai","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.clinre.2025.102741_bib0023","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","article-title":"Epidemiology and natural history of inflammatory bowel diseases","volume":"140","author":"Cosnes","year":"2011","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.clinre.2025.102741_bib0024","first-page":"303","article-title":"Crohn\u2019s disease phenotype, prognosis, and long-term complications: what to expect?","volume":"71","author":"Cosnes","year":"2008","journal-title":"Acta Gastroenterol Belg"},{"issue":"6","key":"10.1016\/j.clinre.2025.102741_bib0025","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/gut.49.6.777","article-title":"Behaviour of Crohn\u2019s disease according to the Vienna classification: changing pattern over the course of the disease","volume":"49","author":"Louis","year":"2001","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.clinre.2025.102741_bib0026","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/gutjnl-2020-323799","article-title":"Predicting endoscopic remission in Crohn\u2019s disease by the modified multiplier SES-CD (MM-SES-CD)","volume":"71","author":"Narula","year":"2022","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.clinre.2025.102741_bib0027","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/ecco-jcc\/jjx130","article-title":"Development of Clinical Prediction Models for Surgery and Complications in Crohn\u2019s Disease","volume":"12","author":"Guizzetti","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.clinre.2025.102741_bib0028","doi-asserted-by":"crossref","DOI":"10.1097\/MCG.0000000000002186","article-title":"Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naive Patients With Crohn\u2019s Disease By Disease Location: results from the EVOLVE Expansion Study","author":"Scharl","year":"2025","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"10.1016\/j.clinre.2025.102741_bib0029","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2025.102741_bib0030","article-title":"Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn\u2019s Disease","author":"Alric","year":"2021","journal-title":"Inflamm Bowel Dis"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125002189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125002189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T12:48:12Z","timestamp":1768222092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740125002189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2210740125002189"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102741","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five-year effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102741"}}